Neuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation

Y. R. Cho, Chan Wha Kim

Research output: Contribution to journalArticle

55 Citations (Scopus)

Abstract

Aims/hypothesis. Previous studies have shown that neuropeptide Y (NPY) gene expression and release are increased in hyperphagic ob/ob mice and diabetic rats. Therefore, we hypothesized that orexigenic agent, NPY, has the effect on the obesity and diabetes. To elucidate the relationship, we have studied the regulatory role of NPY on islet cells. Methods. Isolated islets were incubated with NPY or NPY Y1 receptor specific antagonist, BIBP3226. Proliferation, apoptosis, and Y1 receptor expression were identified by immunohistochemistry. We studied that ERK1/2 mediates the NPY pathway with PD98059 (MAP kinase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), and BIM-1 (protein kinase C inhibitor). After NPY-treated islets were exposed to high glucose, insulin levels were detected. Results. β-Cell replication was enhanced in a dose-dependent manner, but without any changes on the other cells in islet. NPY Y1 receptors were expressed on islet and NPY induced phosphorylation of ERK1/2 rapidly and transiently. PD98059 (MAPK kinase inhibitor) and BIM-1 (protein kinase C inhibitor) inhibited activation of ERK1/2 by NPY, but wortmannin (phosphatidylinositol 3-kinase inhibitor) did not. Exposure of NPY-treated islets to high glucose showed the decreasing trend of insulin secretion. Conclusion/interpretation. Our data suggest that NPY promotes β-cell replication via extracellular signal-regulated kinase activation and inhibits glucose-stimulated insulin secretion.

Original languageEnglish
Pages (from-to)773-780
Number of pages8
JournalBiochemical and Biophysical Research Communications
Volume314
Issue number3
DOIs
Publication statusPublished - 2004 Feb 13

Fingerprint

Neuropeptide Y
Extracellular Signal-Regulated MAP Kinases
Chemical activation
Phosphatidylinositol 3-Kinase
Protein C Inhibitor
Insulin
Protein Kinase Inhibitors
Islets of Langerhans
Glucose
Protein Kinase C
Phosphorylation
Mitogen-Activated Protein Kinase Kinases
Medical problems
Gene expression
Rats
Phosphotransferases
Obesity
Immunohistochemistry
Apoptosis
Gene Expression

Keywords

  • BIBP3226
  • BIM-1
  • Extracellular signal-regulated kinase
  • Insulin
  • Islet
  • Neuropeptide Y
  • PD98059
  • Phosphoinositide 3-kinase
  • Protein kinase C
  • Wortmannin

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Molecular Biology

Cite this

Neuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation. / Cho, Y. R.; Kim, Chan Wha.

In: Biochemical and Biophysical Research Communications, Vol. 314, No. 3, 13.02.2004, p. 773-780.

Research output: Contribution to journalArticle

@article{7011170ee8594f61b4d92bd4c80a2aaa,
title = "Neuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation",
abstract = "Aims/hypothesis. Previous studies have shown that neuropeptide Y (NPY) gene expression and release are increased in hyperphagic ob/ob mice and diabetic rats. Therefore, we hypothesized that orexigenic agent, NPY, has the effect on the obesity and diabetes. To elucidate the relationship, we have studied the regulatory role of NPY on islet cells. Methods. Isolated islets were incubated with NPY or NPY Y1 receptor specific antagonist, BIBP3226. Proliferation, apoptosis, and Y1 receptor expression were identified by immunohistochemistry. We studied that ERK1/2 mediates the NPY pathway with PD98059 (MAP kinase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), and BIM-1 (protein kinase C inhibitor). After NPY-treated islets were exposed to high glucose, insulin levels were detected. Results. β-Cell replication was enhanced in a dose-dependent manner, but without any changes on the other cells in islet. NPY Y1 receptors were expressed on islet and NPY induced phosphorylation of ERK1/2 rapidly and transiently. PD98059 (MAPK kinase inhibitor) and BIM-1 (protein kinase C inhibitor) inhibited activation of ERK1/2 by NPY, but wortmannin (phosphatidylinositol 3-kinase inhibitor) did not. Exposure of NPY-treated islets to high glucose showed the decreasing trend of insulin secretion. Conclusion/interpretation. Our data suggest that NPY promotes β-cell replication via extracellular signal-regulated kinase activation and inhibits glucose-stimulated insulin secretion.",
keywords = "BIBP3226, BIM-1, Extracellular signal-regulated kinase, Insulin, Islet, Neuropeptide Y, PD98059, Phosphoinositide 3-kinase, Protein kinase C, Wortmannin",
author = "Cho, {Y. R.} and Kim, {Chan Wha}",
year = "2004",
month = "2",
day = "13",
doi = "10.1016/j.bbrc.2003.12.170",
language = "English",
volume = "314",
pages = "773--780",
journal = "The BMJ",
issn = "0730-6512",
publisher = "Kluwer Academic Publishers",
number = "3",

}

TY - JOUR

T1 - Neuropeptide Y promotes β-cell replication via extracellular signal-regulated kinase activation

AU - Cho, Y. R.

AU - Kim, Chan Wha

PY - 2004/2/13

Y1 - 2004/2/13

N2 - Aims/hypothesis. Previous studies have shown that neuropeptide Y (NPY) gene expression and release are increased in hyperphagic ob/ob mice and diabetic rats. Therefore, we hypothesized that orexigenic agent, NPY, has the effect on the obesity and diabetes. To elucidate the relationship, we have studied the regulatory role of NPY on islet cells. Methods. Isolated islets were incubated with NPY or NPY Y1 receptor specific antagonist, BIBP3226. Proliferation, apoptosis, and Y1 receptor expression were identified by immunohistochemistry. We studied that ERK1/2 mediates the NPY pathway with PD98059 (MAP kinase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), and BIM-1 (protein kinase C inhibitor). After NPY-treated islets were exposed to high glucose, insulin levels were detected. Results. β-Cell replication was enhanced in a dose-dependent manner, but without any changes on the other cells in islet. NPY Y1 receptors were expressed on islet and NPY induced phosphorylation of ERK1/2 rapidly and transiently. PD98059 (MAPK kinase inhibitor) and BIM-1 (protein kinase C inhibitor) inhibited activation of ERK1/2 by NPY, but wortmannin (phosphatidylinositol 3-kinase inhibitor) did not. Exposure of NPY-treated islets to high glucose showed the decreasing trend of insulin secretion. Conclusion/interpretation. Our data suggest that NPY promotes β-cell replication via extracellular signal-regulated kinase activation and inhibits glucose-stimulated insulin secretion.

AB - Aims/hypothesis. Previous studies have shown that neuropeptide Y (NPY) gene expression and release are increased in hyperphagic ob/ob mice and diabetic rats. Therefore, we hypothesized that orexigenic agent, NPY, has the effect on the obesity and diabetes. To elucidate the relationship, we have studied the regulatory role of NPY on islet cells. Methods. Isolated islets were incubated with NPY or NPY Y1 receptor specific antagonist, BIBP3226. Proliferation, apoptosis, and Y1 receptor expression were identified by immunohistochemistry. We studied that ERK1/2 mediates the NPY pathway with PD98059 (MAP kinase inhibitor), wortmannin (phosphatidylinositol 3-kinase inhibitor), and BIM-1 (protein kinase C inhibitor). After NPY-treated islets were exposed to high glucose, insulin levels were detected. Results. β-Cell replication was enhanced in a dose-dependent manner, but without any changes on the other cells in islet. NPY Y1 receptors were expressed on islet and NPY induced phosphorylation of ERK1/2 rapidly and transiently. PD98059 (MAPK kinase inhibitor) and BIM-1 (protein kinase C inhibitor) inhibited activation of ERK1/2 by NPY, but wortmannin (phosphatidylinositol 3-kinase inhibitor) did not. Exposure of NPY-treated islets to high glucose showed the decreasing trend of insulin secretion. Conclusion/interpretation. Our data suggest that NPY promotes β-cell replication via extracellular signal-regulated kinase activation and inhibits glucose-stimulated insulin secretion.

KW - BIBP3226

KW - BIM-1

KW - Extracellular signal-regulated kinase

KW - Insulin

KW - Islet

KW - Neuropeptide Y

KW - PD98059

KW - Phosphoinositide 3-kinase

KW - Protein kinase C

KW - Wortmannin

UR - http://www.scopus.com/inward/record.url?scp=1642578979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1642578979&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2003.12.170

DO - 10.1016/j.bbrc.2003.12.170

M3 - Article

VL - 314

SP - 773

EP - 780

JO - The BMJ

JF - The BMJ

SN - 0730-6512

IS - 3

ER -